Author Archive for: TG

UK biotech Mestag Therapeutics has raised $40 million and appointed veteran drug developers Lindsey Rolfe as chief medical officer and Pascal Merchiers as chief development officer, as the company prepares to start its first clinical trial in cancer in mid-2026. The new financing brings total capital committed to the Cambridge-based company to more than $95 million, following its $11 million launch round in April 2021 and a seed extension that took total seed financing to $45 million in August 2021.

London-based Ternary Therapeutics has raised a €4.1 million seed round to expand its platform for designing molecular glue drugs, with Paris-based VC daphni leading the financing alongside Pace Ventures, i&i Biotech Fund and Future Planet Capital.

VALANX Biotech has raised €3 million in a Series A funding round to advance an antibody-drug conjugate (ADC) targeting LIV-1 for triple-negative breast cancer. The developments are currently still at the preclinical stage.

Cost-cutting measures sometimes arrive wrapped in reassuring language. “Horizon” is the name Evotec SE has given to the next stage of its restructuring programme, which will affect additional sites and their employees. Up to 800 staff may find it difficult to look past the polished wording.

The Mainz-based biotech company BioNTech is facing a historic leadership change as the minds behind the COVID-19 vaccine prepare for a fresh start. Uğur Şahin and Özlem Türeci plan to focus entirely on mRNA platform technology and will launch a spin-off at the end of the year.